You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective
Contributor:
Bose, Debdipta;
Gogtay, Nithya Jaideep;
Rajan, Sujeet K
Published:
Medknow, 2021
Published in:
Lung India, 38 (2021) 4, Seite 382-386
Language:
English
DOI:
10.4103/lungindia.lungindia_883_20
ISSN:
0970-2113
Origination:
Footnote:
Description:
Remdesivir, a repurposed antiviral, was first accorded approval by the US Food Drug Administration (FDA) for the treatment of COVID-19 which necessitates hospitalization. However, the interim data of SOLIDARITY trial revealed no benefits with remdesivir for COVID-19 patients which led immediate debates in social media and the press about the utility of the drug. Both preclinical and clinical data demonstrated its efficacy in COVID-19. The recently concluded ACTT-1 trial showed its efficacy in reducing the duration of hospital stay which is of utmost importance for a country like India where reduction in bed occupancy can save lives of many and eases the financial burden of patient and government. Our benefit-risk analysis of ACTT-1 trial also favored the use of remdesivir over standard of care. The SOLIDARITY trial was fundamentally different from other clinical trials on remdesivir with respect to its design, adaptive nature, and selection of endpoints. Moreover, the success of antiviral therapy also depends on the timing of initiation and combination with other drugs. Hence we believe that drugs like Remdesivir are very important for countries like India where soft end points such as time to recovery and clinical improvement and early discharge become extremely significant during a pandemic.